Document is current
Any future updates will be listed below
-
Authors
Pharo, Heidi Dietrichson
Jeanmougin, Marine
Ager-Wick, Eirill
Vedeld, Hege Marie
Sørbø, Anne Klara
Dahl, Christina
Larsen, Louise Katrine
Honne, Hilde
Brandt-Winge, Sara
Five, May-Britt
Monteiro-Reis, Sara
Henrique, Rui
Jeronimo, Carmen
Steven, Kenneth
Wahlqvist, Rolf
Guldberg, Per
Lind, Guro Elisabeth
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF (40093)
Cancer-BIOTEK (254834)
- License Information
-
More Information
Article History
Received: 6 July 2022
Accepted: 11 September 2022
First Online: 17 September 2022
Declarations
:
: This study was carried out according to the Helsinki declaration, and the included research biobanks have been registered according to national legislation. The study has been approved by the Regional Committee for Medical and Health Research Ethics, which requires that informed consent is obtained from patients enrolled in the study.
: Not applicable.
: GEL certifies that all conflicts of interest are the following: GEL, CJ and RH are named on a patent (WO/2012/052844) proposing <i>VIM</i> as a biomarker for detection of bladder cancer, granted in US (US9797016) and EP (2,630,261). GEL, RW, CJ and HDP are named on a pending PCT patent application (WO/2020/099938) covering the biomarkers published in this study. GEL, MJ and HDP are named on two pending US national applications (US/2019/0221286 and WO/2019/106149) covering the 4Plex control and PoDCall algorithm used in the present study for normalization of DNA methylation ddPCR results. The remaining authors have nothing to disclose.
